DRS 2021 POSTERS

TOP 5 POSTERS

#101 - Proactive management using calcipotriene/betamethasone dipropionate foam in patients with plaque psoriasis prolongs time with a health-related quality of life improvement, compared with reactive management

Linda Stein Gold MD, Nanna Nyholm MSc, Henrik Thoning Ph.Ahmc MD, D, Piergiacomo Calzavara-Pinton MD
#104 - Mean Percentage Improvement in Psoriasis Area and Severity Index (PASI) Response and Absolute PASI through-5 Years of Continuous Treatment with Guselkumab in VOYAGE-1

Joseph F. Merola, Luis Puig, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Andrew Blauvelt
​
#105 - Switch Rates Among Psoriasis Patients Initiating Apremilast or Biologics

Jashin J. Wu, MD; Julia Zhu, MPH, MS; Manasi Suryavanshi, PhD, MPH; Mayank Mittal, BE(IT); Vardhaman Patel, MS, PhD; David Davidson, MS PA-C; Lauren Seigel, MS


​
#106 - Rapid Itch Improvement in Children With Severe Atopic Dermatitis Treated With Dupilumab: A Phase 3 Subset Analysis

Gil Yosipovitch, MD; Jonathan I. Silverberg, MD; Jashin J. Wu, MD; Zhen Chen, PhD; Parul Shah, PharmD; Randy Prescilla, MD



​
#108 - Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis (AD): Results From an Open-Label Extension (OLE) Trial up to 172 Weeks

Andreas Wollenberg, Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Andrew Blauvelt, Jacob P. Thyssen, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Jignesh Vakil, Ainara Rodríguez Marco, Noah Levit

ADDITIONAL POSTERS

#102 - Long-term treatment of plaque psoriasis with calcipotriene/betamethasone dipropionate foam was locally well tolerated and not associated with skin atrophy

​Leon Kircik MD, Marie Holst Mørch MS, Bibi Petersen MD Ph.D, Monika Liljedahl MD Ph.D, Andreas Wollenberg MD
#103 - Bullous pemphigoid superimposed on psoriasis

​Vivian Liu MS, Dayoung Ko MD, Marissa Ceresnie DO, Chauncey McHargue MD
#107 - Alopecia areata associated with duloxetine

Debra Lee BS, Usman Ghumman MD, Peter Thompson MD






​
#109 - Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis

​Andrew Blauvelt, Jean-Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Hidehisa Saeki





​
​
#110 - COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial

​Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky




​
​
#111 - Long-term maintenance of efficacy in patients with moderate-to-severe atopic dermatitis with tralokinumab monotherapy: combined results from two phase 3, randomized, double-blinded, placebo-controlled trials (ECZTRA 1 and 2)

​Andrew Blauvelt, Andreas Wollenberg, Andrew Pink, Margitta Worm, Ketty Peris, April Armstrong, Lynda Spelman, Hidehisa Saeki, Charles Lynde, Jacob Thyssen, Pedro Herranz, Sebastien Barbarot, Louise Abildgaard Steffensen, Alexandra Kuznetsova, Eric Simpson
​
#112 - Impact of Abrocitinib on Itch, Sleep, Skin Pain, and Psychological Stress in Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis From JADE Monotherapy Trials

​Anthony Bewley, Jacob P. Thyssen, Wing Sin Chiu, Ricardo Rojo, Pinaki Biswas, Claire Feeney, Marco DiBonaventura, Laurent Misery, Sonja Ständer, Michael Cork


​
#113 - Efficacy of Abrocitinib Monotherapy in Patients With Atopic Dermatitis With Prior Exposure to Systemic Treatments: Pooled Results From JADE MONO-1 and JADE MONO-2 Studies

​Mahreen Ameen, Wing Sin Chiu, Ricardo Rojo, Pinaki Biswas, William Romero, Michael Ardern-Jones



​
#114 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

​Diamant Thaçi, MD, Kenneth Gordon, MD, Melinda Gooderham, MD, Bruce Strober, MD, Neil J Korman, MD, Subhashis Banerjee, MD, Elizabeth Colston, MD, Jonghyeon Kim, PhD, John Throup, PhD, Akimichi Morita, MD
#115 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Neil J Korman, MD, Kim Papp, MD, Jerry Bagel, MD, Peter Foley, MD, Akimichi Morita, MD, Subhashis Banerjee, MD, Elizabeth Colston, MD, Tao Wang, PhD, John Throup, PhD, Diamant Thaçi, MD